Literature DB >> 10913289

Interaction of cardiac troponin C with Ca(2+) sensitizer EMD 57033 and cardiac troponin I inhibitory peptide.

M X Li1, L Spyracopoulos, N Beier, J A Putkey, B D Sykes.   

Abstract

The binding of Ca(2+) to cardiac troponin C (cTnC) triggers contraction in cardiac muscle. In diseased heart, the myocardium is often desensitized to Ca(2+), leading to weak cardiac contractility. Compounds that can sensitize cardiac muscle to Ca(2+) would have potential therapeutic value in treating heart failure. The thiadiazinone derivative EMD 57033 is an identified 'Ca(2+) sensitizer', and cTnC is a potential target of the drug. In this work, we used 2D ¿(1)H, (15)N¿-HSQC NMR spectroscopy to monitor the binding of EMD 57033 to cTnC in the Ca(2+)-saturated state. By mapping the chemical shift changes to the structure of cTnC, EMD 57033 is found to bind to the C-domain of cTnC. To test whether EMD 57033 competes with cardiac TnI (cTnI) for cTnC and interferes with the inhibitory function, we examined the interaction of cTnC with an inhibitory cTnI peptide (residues 128-147, cIp) in the absence and presence of EMD 57033, respectively. cTnC was also titrated with EMD 57033 in the presence of cIp. The results show that although both the drug and cIp interact with the C-domain of cTnC, they do not displace each other, suggesting noncompetitive binding sites for the two targets. Detailed chemical shift mapping of the binding sites reveals that the regions encompassing helix G-loop IV-helix H are more affected by EMD 57033, while residues located on helix E-loop III-helix F and the linker between sites III and IV are more affected by cIp. In both cases, the binding stoichiometry is 1:1. The binding affinities for the drug are 8.0 +/- 1.8 and 7.4 +/- 4.8 microM in the absence and presence of cIp, respectively, while those for the peptide are 78.2 +/- 10.3 and 99.2 +/- 30.0 microM in the absence and presence of EMD 57033, respectively. These findings suggest that EMD 57033 may exert its positive inotropic effect by not directly enhancing Ca(2+) binding to the Ca(2+) regulatory site of cTnC, but by binding to the structural domain of cTnC, modulating the interaction between cTnC and other thin filament proteins, and increasing the apparent Ca(2+) sensitivity of the contractile system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913289     DOI: 10.1021/bi000473i

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  A novel approach for assessing macromolecular complexes combining soft-docking calculations with NMR data.

Authors:  X J Morelli; P N Palma; F Guerlesquin; A C Rigby
Journal:  Protein Sci       Date:  2001-10       Impact factor: 6.725

2.  Hypertrophic cardiomyopathy-linked mutation D145E drastically alters calcium binding by the C-domain of cardiac troponin C.

Authors:  Nicholas Swindle; Svetlana B Tikunova
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

3.  High-yield expression of isotopically labeled peptides for use in NMR studies.

Authors:  Darrin A Lindhout; Angela Thiessen; Dean Schieve; Brian D Sykes
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

4.  Fluorescence Based Characterization of Calcium Sensitizer Action on the Troponin Complex.

Authors:  William Schlecht; King-Lun Li; Dehong Hu; Wenji Dong
Journal:  Chem Biol Drug Des       Date:  2015-09-16       Impact factor: 2.817

Review 5.  Structural based insights into the role of troponin in cardiac muscle pathophysiology.

Authors:  Monica X Li; Xu Wang; Brian D Sykes
Journal:  J Muscle Res Cell Motil       Date:  2005-02-09       Impact factor: 2.698

Review 6.  Interaction of cardiac troponin with cardiotonic drugs: a structural perspective.

Authors:  Monica X Li; Ian M Robertson; Brian D Sykes
Journal:  Biochem Biophys Res Commun       Date:  2007-12-26       Impact factor: 3.575

7.  EMD 57033 partially reverses ventilator-induced diaphragm muscle fibre calcium desensitisation.

Authors:  Julien Ochala; Peter J Radell; Lars I Eriksson; Lars Larsson
Journal:  Pflugers Arch       Date:  2009-10-02       Impact factor: 3.657

8.  Structure of trans-resveratrol in complex with the cardiac regulatory protein troponin C.

Authors:  Sandra E Pineda-Sanabria; Ian M Robertson; Brian D Sykes
Journal:  Biochemistry       Date:  2011-01-27       Impact factor: 3.162

9.  Enhanced troponin I binding explains the functional changes produced by the hypertrophic cardiomyopathy mutation A8V of cardiac troponin C.

Authors:  Henry G Zot; Javier E Hasbun; Clara A Michell; Maicon Landim-Vieira; Jose R Pinto
Journal:  Arch Biochem Biophys       Date:  2016-03-11       Impact factor: 4.013

10.  Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex.

Authors:  Ian M Robertson; Olga K Baryshnikova; Monica X Li; Brian D Sykes
Journal:  Biochemistry       Date:  2008-06-21       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.